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 2 
Abstract 
Background: Heparin-induced thrombocytopenia (HIT) is a severe side effect of heparin 
treatment caused by platelet activating IgG antibodies generated against the platelet factor 4 
(PF4)-heparin complex. Thrombocytopenia and thrombosis are the leading clinical symptoms 
of HIT.  
Methods: The clinical pretest probability of HIT was evaluated by the 4T score system. 
Laboratory testing of HIT was performed by immunological detection of antibodies against 
PF4-heparin complex (EIA) and two functional assays. Heparin-dependent activation of 
donor platelets by patient plasma was detected by flow cytometry. Increased binding of 
Annexin-V to platelets and elevated number of platelet-derived microparticles (PMP) were 
the indicators of platelet activation.  
Results: EIA for IgG isotype HIT antibodies was performed in 405 suspected HIT 
patients. Based on negative EIA results HIT was excluded in 365 (90%) of cases. In 40 
patients with positive EIA test result functional tests were performed. Platelet activating 
antibodies were detected in 17 cases by Annexin V binding. PMP count analysis provided 
nearly identical results. The probability of a positive flow cytometric assay result was higher 
in patients with elevated antibody titer. 71% of patients with positive EIA and functional 
assay had thrombosis. 
Conclusions: EIA is an important first line laboratory test in the diagnosis of HIT, 
however, HIT must be confirmed by a functional test. Annexin V binding and PMP assays 
using flow cytometry are functional HIT tests convenient in a clinical diagnostic laboratory. 
The positive results of functional assays may predict the onset of thrombosis. 
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INTRODUCTION 
 
Heparin-induced thrombocytopenia (HIT) is an immune response-mediated severe adverse 
effect of anticoagulant therapy by unfractionated (UFH) or low-molecular weight heparin 
(LMWH). Major clinical symptoms of HIT are thrombocytopenia and thrombosis due to the 
generation of IgG isotype HIT antibodies that recognize platelet factor 4 (PF4) bound to 
heparin. It causes heparin-dependent platelet activation through cross-linking FcγIIa 
receptors leading to the release of prothrombotic platelet-derived microparticles (PMPs) with 
platelet consumption and severe thrombocytopenia (1,2). Due to the severity of HIT, early 
and accurate diagnosis is essential to initiate a proper treatment, i.e. the cessation of heparin 
with simultaneous application of an alternative anticoagulant therapy in order to reduce the 
risk of thrombosis, organ failure, amputation or death (3).  
The laboratory evaluation for clinically suspected HIT should focus on the detection of 
heparin-dependent platelet activation induced by HIT antibodies (4). Since testing is 
expensive and time-consuming, first the calculation of the 4T score based on four criteria 
(thrombocytopenia, timing of platelet count fall, thrombosis, and other causes for 
thrombocytopenia) needs to precede laboratory testing for HIT (5). The 4T score system 
calculates the pretest probability of HIT, it has a high negative predictive value. HIT is 
unlikely in patients with a low pretest probability of HIT, however, suspected HIT has to be 
validated by laboratory tests.  
Two types of laboratory approaches are used for the diagnosis of HIT: (i) immunoassays 
for the detection of antibodies against PF4-heparin complex, and (ii) functional assays to 
detect the platelet activating potential of HIT antibodies (6). Immunoassays, especially the 
IgG specific solid-phase enzyme immunoassay (EIA), have a high negative predictive value, 
since negative antibody result excludes HIT (1,7,8). Previous studies have suggested that the 
degree of positivity of the immunoassay should be taken into consideration: the higher the 
antibody titer, the higher the probability of thrombosis (9-11).  
In case of a positive immunoassay result, a functional test must be performed to detect the 
platelet activating HIT antibodies. The gold standard method for this assay is the serotonin 
release assay (SRA) that measures 
14
C-serotonin released from activated 
14
C-serotonin loaded 
washed donor platelets (12). The other frequently used functional assay is the heparin 
induced platelet activation test (HIPA), which detects washed donor platelet aggregation in 
the presence of patient plasma containing HIT antibody (13). Several years ago a sensitive 
and specific flow cytometric functional assay was described for HIT testing, in which HIT 
Page 6 of 22
John Wiley and Sons, Inc.
Cytometry: Part B - Clinical Cytometry
This article is protected by copyright. All rights reserved.
 4 
antibodies in the presence of therapeutic concentration of heparin activated healthy donor’s 
platelet rich plasma and the translocation of phosphatidylserine to the surface of activated 
platelets could be observed by using fluorescently labeled Annexin V (14). The elevated 
number of PMPs generated during platelet activation was also suggested as a surrogate 
marker for identifying HIT (15, 16).  
Since nowadays flow cytometers are usually available in larger clinical diagnostic 
laboratories we thought to take advantage of the detection of Annexin V positivity and PMP 
generation by activated platelets as a complementary approach to diagnose functional HIT 
antibodies. The aim of this study was to evaluate the performance of this flow cytometric 
functional assay in relation to the 4T score system, optical density (OD) results of EIA and 
the development of thrombosis. This way the study intended to provide additional data for 
the assessment of this functional assay in the diagnosis of HIT. 
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MATERIALS AND METHODS 
Study design, Patients and Samples 
Between January 2009 and December 2014 plasma samples of 405 patients with 
physician-suspected HIT were evaluated in order to confirm or exclude the clinical diagnosis. 
HIT was suspected if there was a decrease in platelet count after the initiation of UFH or 
LMWH therapy in these hospitalized patients. We draw blood from healthy controls (n=4) 
and from patients receiving heparin treatment without suspected HIT (n=4) in order to 
validate our HIT assays. Plasma samples were obtained from 0.105 M trisodium citrate-
anticoagulated whole blood in Vacutainer tubes (Becton Dickinson, San Jose, CA, USA) by 
the standard centrifugation procedure (1500 g, 15 min, 22
o
C).  
 
4T score 
In order to calculate the 4T score value for patients, the clinical pathologist contacted the 
referring physician, and prior to the laboratory tests each patient was evaluated according to 
the four suggested criteria as published by Lo et al. to establish the clinical pretest probability 
of HIT (17). Clinical 4T scores were grouped as follows: 0–3: low probability; 4–5: 
intermediate probability; 6–8: high probability of HIT.  
 
Solid-phase enzyme immunoassay (EIA) 
To detect the IgG isotype anti-PF4/heparin antibodies the commercially available 
ZYMUTEST HIA IgG (Hyphen BioMed, Neuville-sur-Oise, France) kit was used according 
to the manufacturer’s instructions. The measured OD value was directly proportional to the 
amount of IgG isotype heparin-dependent antibodies present in the patient’s plasma. 
According to the OD values the result of the assay was graded as negative (Abs450 ≤ 0.5, 
including the Abs450 values between 0.3-0.5 as grey zone), or positive (Abs450 > 0.5). The EIA 
test was carried out for all patients (n=405) independently from the 4T score values. 
 
Flow cytometric functional assay 
The functional test was carried out in borderline patients (OD=0.3-0.5; n=11) and patients 
with positive EIA results (n=40). In order to validate the flow cytometric assay, the test was 
also carried out in 40 randomly chosen patients with negative EIA results in addition to the 
healthy controls (n=4) and patients receiving heparin treatment without suspected HIT (n=4). 
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The Annexin V-binding assay described by Tomer et al. (14) was performed with some 
minor modifications. Platelet rich plasma (PRP) was obtained from trisodium citrate-
anticoagulated blood of healthy donors having O blood type. To avoid donor platelet 
variation, during our tests PRP was obtained from the same selected high-responder donors 
as described previously (18). Donor PRP was separated by centrifugation (150 g, 5 min, 
22
o
C). Ten µL PRP was added to 10 µL patient plasma. The mixture was incubated in the 
presence of therapeutic (0.3 IU/mL) and excessive dose (100 IU/mL) of UFH in a final 
volume of 50 µL adjusted by PBS. HIT antibodies induced platelet activation only in the 
presence of therapeutic concentration of heparin, while excess of heparin disrupted antigen-
antibody complexes, thus attenuated platelet activation (19). As positive controls, in each 
series of measurements we used patient plasma, which was previously found to be positive in 
our functional assay. After a 30 min incubation at 27
o
C, 5 µL aliquots were removed from 
each tube and incubated in the presence of 5 µL phycoerythrin (PE)-labeled 20-fold diluted 
anti-CD41 antibody (Dako, Glostrup Denmark) for platelet identification and 1 µL Annexin 
V-fluorescein-isothiocyanate (FITC) (Becton Dickinson) for the detection of activated 
platelets. The samples were adjusted to a final volume of 50 µL with 0.02 M HEPES buffer 
(pH 7.3) containing 2.2 mM Ca
2+
. After 15 min incubation at room temperature in the dark, 
samples were supplemented with 400 µL Ca
2+
-containing HEPES buffer (pH 7.3) and 
analyzed by FACScan flow cytometer (Becton Dickinson); platelet acquisition time was 1 
min with high flow rate. Platelets were identified by the immunofluorescence of the PE-
labeled anti-CD41 antibody. In negative control samples, PRP without patient plasma but 
with 0.3 IU/mL UFH, less than 5% of platelets demonstrated Annexin V-binding. According 
to the report of Poley and Mempel in which Annexin V-binding flow cytometric test was 
compared to HIPA test, the result of the Annexin V-binding assay was considered positive if: 
(i) at least 11% of platelets were Annexin V positive after treatment with 0.3 IU/mL heparin, 
(ii) and the ratio of the percentage of Annexin V positive platelets generated in the presence 
of 0.3 IU/mL and that of 100 IU/mL of heparin was more than 1.5 (20). PMPs produced by 
activated platelets were identified by size-selection based on their forward (FSC) and side 
scatter (SSC) properties. Latex spheres were used to test the correctness of PMP gating. The 
result of the PMP assay was expressed as the ratio between the number of PMPs generated at 
0.3 IU/mL and 100 IU/mL of heparin. Positive result was considered when the PMP ratio 
was 1.5 or higher.  
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Statistical analysis 
Mean values of the heparin-dependent EIA OD parameters of patient groups with either 
positive or negative Annexin V-binding functional assay results were compared by unpaired 
Student’s t-test. Logistic regression analysis was used to estimate the effect of EIA OD units 
(continuous explanatory variable) on the outcome of the flow cytometric functional assays 
and on the risk of thrombosis (dichotomous dependent variables). Odds ratio with 95% 
confidence intervals was calculated using STATA 9.0 software, a P value <0.05 was 
considered statistically significant. 
 
Page 10 of 22
John Wiley and Sons, Inc.
Cytometry: Part B - Clinical Cytometry
This article is protected by copyright. All rights reserved.
 8 
RESULTS 
Patient characteristics and laboratory test results in HIT-suspected patients 
Out of the 405 IgG-specific EIA tests carried out on suspected HIT patients, 365 proved to 
be negative (354 patients with OD=<0.3 and 11 patients with borderline result, OD=0.3-0.5).  
On the basis of these negative immunoassay results HIT was excluded in 90% of all enrolled 
patients (365/405). Plasma samples of the remaining 40 patients contained heparin-dependent 
IgG isotype antibody (EIA OD range: 0.589–3.382). The functional assays were performed in 
samples of all EIA positive patients (n=40) in addition to 40 randomly chosen EIA negative 
patients, 11 borderline/grey zone cases, 4 healthy controls (EIA OD=<0.3) and 4 patients 
receiving heparin treatment without suspected HIT (EIA OD=<0.3). Out of the 40 EIA 
positive patients the Annexin V-binding assay was positive in 17, while the PMP assay was 
positive in 14 cases. In two cases (one EIA positive and one EIA borderline patient) PMP 
results were not available. Similarly to controls, patients with borderline or negative EIA 
results had negative functional assay results confirming HIT negativity.  
Representative results of the two functional flow cytometric assays are depicted in Fig. 1. 
HIT negative control plasma did not activate donor platelets, however, plasma sample of a 
HIT patient stimulated donor platelets in the presence of pharmacological heparin 
concentration (0.3 IU/mL). The fact that in the presence of excessive amount of heparin (100 
IU/mL) platelets were not activated - or significantly less activated - proves the strict heparin 
concentration dependency of platelet activation (19). The clinical and laboratory data of the 
17 patients with positive Annexin V-binding functional assay results are shown in Table 1. 
The majority of the patients (n=11) were surgical cases, the remaining 6 patients were 
medical cases. Almost 2/3rd of these patients were female (64.7%), which was in agreement 
with a previous report (21). In all 17 HIT patients, heparin administration was discontinued 
and 14 patients were switched to alternative anticoagulants (lepirudin or rivaroxaban). After 
the cessation of heparin treatment, platelet count recovered which was a clear indicator of 
HIT except for 3 patients who subsequently died. In Table 2 we summarized the clinical and 
laboratory data of EIA positive but functional test negative (n= 23) patients, including 10 
medical and 13 surgical cases. Out of these 23 cases 18 patients were not treated with an 
alternative anticoagulant. Seven of these 18 patients died from causes other than thrombosis, 
their death were due to multiorgan failure, in 7 patients the platelet count recovered 
spontaneously. In the remaining 4 cases, platelet count did not recover, however 
thrombocytopenia had causes other than HIT. Five patients were given alternative 
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anticoagulants, in 2 of them the platelet count remained low, in 3 cases (1 medical, 2 cardiac 
surgery cases) the platelet count recovered. The medical and one of the surgical patients had 
gastrointestinal bleeding and they died one month after the laboratory testing for HIT due to 
hypoxia and septicemia, respectively. It is to be noted that none of the Annexin V positive 
patients had low pretest probability of HIT based on their 4T score, their mean 4T score 
value was 5.71. The mean 4T score of EIA positive but functional assays negative patients 
was 4.22 while that of EIA negative patients was 3.63.  
 
Association of heparin-dependent antibody level with functional test positivity 
In patients with positive (n=40) and borderline (n=11) EIA results the functional assays 
were also carried out. First, the association between the IgG isotype EIA OD values with the 
outcome of the Annexin V-binding assay (Fig. 2A) and with that of PMP assay (Fig. 2B) 
were analyzed, only those patients are shown for whom both assay results are available 
(n=49). There were two Annexin V-binding positive cases in which negative results were 
obtained with the PMP assay (Table 1). There was a positive association between the EIA 
OD values and the functional assay positivity: the higher the IgG isotype EIA OD value was 
measured, the higher the probability of a positive functional assay result was found. 
In patients with a negative Annexin V-binding assay result and a positive EIA test (n=23) 
the average EIA OD value was 1.330. However, in those with positive functional assay 
results (n=17), the average EIA OD value was 2.544, which was significantly higher than the 
OD values in the former group (P<0.0001).  
We used a logistic regression analysis to calculate the strength of the association between 
IgG isotype EIA OD values and the dichotomous outcome of the two flow cytometric 
functional assays. The quantitative OD results of the EIA test were significantly associated 
with the positive outcome of the Annexin V-binding assay and PMP assay. The odds of 
positive Annexin V-binding assay result was elevated for each unit increment in the 
corresponding independent variable (OD unit) as follows: OR: 6.38 (95%CI, 2.58–15.78; P= 
0.0001); for the PMP assay these values were: OR: 4.64 (95%CI, 2.08–10.35; P= 0.0002).  
 
Association of heparin-dependent antibody level and functional test positivity with 
thrombosis 
Since the most severe adverse event associated with HIT is thrombosis, we statistically 
analyzed the relationship between heparin-dependent antibody levels and the frequency of 
thrombotic events. Fig. 2C demonstrates that higher level of heparin-dependent antibody was 
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associated with increased probability of thrombosis. Among subjects with positive EIA OD 
values (n=40) the overall rate of thrombotic events was 30% (12/40). The logistic regression 
analysis showed that the OD values of the EIA test were significantly associated with the 
presence of thrombosis in patients. The odds for having thrombosis was raised for each unit 
elevation in the OD value: OR: 3.05 (95%CI, 1.51–6.18; P= 0.002).  
The positive flow cytometric assay results detecting platelet activation also showed a good 
agreement with the presence of thrombosis in our group of patients (Table 1, Figs. 2A and 
B). 70.6% (12/17) of patients with both EIA and Annexin V test positivity showed 
thrombosis (Table 1). The majority of PMP positive cases, 10 out of 14, also suffered from 
thrombosis. 
 
Association of clinical pretest probability of HIT and functional test positivity 
We also assessed the pretest probability of HIT by applying the 4T score system in our 
patient cohort. Based on these score values, EIA positive patients were classified as groups 
with low (n=5), intermediate (n=26) and high (n=9) pretest probability of HIT. In individuals 
with low pretest probability of HIT, the functional assay results were negative, showing that 
platelet activating antibodies were not present in these samples even in cases with high 
antibody titer (Fig. 3). At intermediate pretest probability the antibody titer was higher in 
patients possessing platelet-activating antibodies, and the functional tests were positive for all 
patients with an OD≥2.633. With a single exception, all patients with high pretest probability 
of HIT had positive Annexin V binding assay result, as well. There was a single patient with 
high 4T score and thrombosis in whom a relatively low EIA OD value (OD=0.589) was 
associated with positive Annexin V-binding and negative PMP assay result.  
 
 
DISCUSSION 
In our single center study, we assessed the performance of the Annexin V-binding flow 
cytometric assay in the diagnosis of HIT. The results of this functional assay were analyzed 
in comparison with the OD values of EIA assay to determine the association between the 
antibody titer and platelet activating potential of the plasma sample. Functional test results 
and EIA OD values were also compared to the 4T score values and the occurrence of 
thrombosis.   
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So far only a limited number of studies have been published on this flow cytometric 
functional assay. Our intention was to provide additional data to assess the clinical usefulness 
of this assay in the laboratory diagnosis of HIT. Moreover, this is the first study, which 
compares the flow cytometric functional assay results with the distribution of EIA OD 
values. We found a significant positive association between the OD values and the positivity 
of the functional assay result. Warkentin et al. also reported a positive association between 
the degree of the EIA OD positivity and the positive outcome of the SRA test (10). The fact 
that the magnitude of the EIA OD value was positively associated with the platelet-activating 
potential of the HIT antibody emphasized the importance of the exact EIA OD value in the 
interpretation of the immunoassay results (4,9,22).  
During our six-year long study, 405 suspected HIT patients were investigated. In 365 
patients representing 90% of all suspected cases, HIT was excluded based on the low EIA 
OD values (OD<0.5). Similar finding has been published previously (1). On the other hand, 
the combined use of EIA and Annexin V-binding test confirmed HIT in 4.2% of all cases 
(17/405). In a previous study Greinacher et al. reported that immunoassay and washed 
platelet activation assay, HIPA verified the diagnosis of HIT in almost 6% of suspected HIT 
patients (1). Among our EIA positive patients 42.5% (17/40) had positive results with 
Annexin V-binding flow cytometric functional assay, while the same ratio was higher, 48.6% 
(17/35) among the EIA positive and clinically suspected HIT patients (4T score>3). 
According to previous publications platelet activating antibodies are present in only one third 
to one half of EIA positive patients (1,23,24). The actual value strongly depends on the 
patient population and the antibody class specificity of the EIA assay used for diagnosis. Our 
result is in good agreement with these data. The results suggest that the disease might be 
considerably over-diagnosed using only EIA assay without a functional test; EIA may detect 
non-platelet activating antibodies as well (22). The PMP region analysis is a convenient flow 
assay to predict the platelet activating ability of the patient plasma, however, it proved to be 
somewhat less sensitive for predicting thrombosis at lower antibody OD values.  
We carried out the laboratory investigation for all physician-suspected HIT patients, and 
the results supported the recommendation that in patients with a low pretest probability score 
(4T score ≤ 3) HIT could be confidently excluded without laboratory testing. None of our 
EIA positive patients with low 4T score had positive functional assay result and thrombosis 
in this large cohort of HIT suspected patients.  
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According to the literature 69% of the EIA and SRA positive patients suffered from 
thrombosis (25). In our study 71% (12/17) of patients with EIA and Annexin V-binding 
functional test positivity had thrombosis, which means that 30% (12/40) of the immunoassay 
positive cases had thrombotic events. It is noteworthy that these patients had high OD values 
in their EIA test with a single exception. We also found that higher heparin-dependent 
antibody titer (expressed as OD value) was significantly associated with an increased 
probability of thrombosis.  
A limitation of our study is that we did not compare flow cytometric results with that of an 
established reference test, like SRA or HIPA. SRA is a sensitive test for laboratory 
confirmation of HIT, however, it is not suitable for routine testing since it uses radioactive 
substances [
14
C-serotonin]. It is a technically demanding, time-consuming test (12, 26) hence, 
the test is not available in most clinical routine laboratories restricting its use for clinicians. 
The other washed platelet assay, HIPA is also a specific and sensitive test to detect clinically 
significant HIT antibodies. However, the appropriate donor platelet selection is essential for 
correct results in HIPA and the critically important washing steps also represent a crucial 
handling problem (27). Indeed, in our preliminary experiments in a series of trisodium citrated 
samples, whole blood displayed 1.6% of mean platelet P-selectin positivity that became only 
slightly elevated in PRP (3.5%), but was significantly higher in washed platelets (30-41%) 
(data not shown). This means that washed platelets used for both SRA and HIPA became 
considerably activated already during the isolation procedures that may bias further functional 
responses. 
The Annexin V-binding flow cytometric assay was shown to be an accurate test for the 
diagnosis of HIT. Previously Tomer then Poley and Mempel compared its sensitivity and 
specificity to these of the gold standard SRA and HIPA tests. The sensitivity of the flow 
cytometric assay was found to be 95% and 100% when it was compared to SRA and HIPA 
respectively, the specificity of the assay was 100% in both comparisons (14, 20).  
Even in early reports about the laboratory diagnosis of HIT the authors suggested that a 
flow cytometric assay can serve as a fast, accurate and cost effective test for this sometimes 
life-threating state, but as they described a special skill is needed to run a flow cytometer (20). 
Even in recent publications about the diagnosis of HIT, flow cytometry is described as one of 
the future possibilities (16,18,28).  In the past decade, flow cytometry has become an 
everyday practice in clinical laboratories by the introduction of novel compact size flow 
cytometers with user friendly softwares and it is gradually gaining space in confirming the 
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diagnosis of HIT (24, 29-33). Based on our current results it is concluded, that flow cytometry 
reliably predicts clinical outcome and is a useful aid in avoiding the over-diagnosis of HIT. 
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Figure Legends 
 
Fig. 1. Flow cytometric functional assays for HIT. Results with a representative HIT 
negative control and a HIT positive patient’s sample. Donor platelet-rich plasma was 
incubated with control plasma or with plasma from a HIT patient in the presence of 
pharmacological concentration (0.3 IU/mL) or excessive dose (100 IU/mL) of heparin. (A) 
Platelet-derived microparticles were identified by size-selection, the number of generated 
microparticles is provided in the lower left rectangle. (B) Platelet activation induced by HIT 
plasma in the presence of 0.3 IU/mL of heparin was detected by the elevated percentage of 
Annexin V positive platelets (shown in the upper right quadrant).  
 
Fig. 2.  Association between the IgG-specific anti-PF4/heparin antibody (EIA-IgG) titer 
with (A) the result of the flow cytometric assay detecting Annexin V-binding, (B) the results 
of PMP determination, and (C) thrombotic outcome.  
 
Fig. 3.  Distribution of the platelet activating and non-activating IgG-specific antibody 
titer (EIA-IgG OD units) according to the 4T score. Open circle: negative for Annexin V 
binding and platelet microparticle (PMP) assay; solid circle: positive for both assays; half 
filled circle: Annexin V assay positive, PMP assay negative; solid square: Annexin V binding 
positive, PMP was not investigated.  
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Table 1. Laboratory and clinical data of HIT patients with positive Annexin V-binding assay result 
 Patient  Laboratory results     Clinical data      Follow up   
 Male (M)/ EIA Annexin V Platelet MP  4T score Thrombosis Surgical  or  Alternative Platelet count 
 Female (F) (OD) binding assay assay    medical patient  anticoagulant recovery 
1 M 3.382 + +  5 + surgical  + + 
2 M 3.273 + +  7 + surgical  + + 
3 F 3.262 + +  5 - surgical  + + 
4 F 3.206 + +  6 + surgical  - death 
5 M 3.028 + +  4 - medical  + + 
6 F 3.010 + +  5 + surgical  - death 
7 F 2.967 + not determined  5 - surgical  + + 
8 F 2.920 + +  5 + surgical  + + 
9 F 2.898 + +  6 + medical  + + 
10 F 2.798 + +  5 - surgical  + + 
11 F 2.633 + +  5 - surgical  + + 
12 M 2.441 + +  7 + medical  + death 
13 M 2.341 + +  7 + surgical  - + 
14 M 1.801 + +  7 + medical  + + 
15 F 1.405 + +  7 + surgical  + + 
16 F 1.303 + -  5 + medical  + + 
17 F 0.589 + -  6 + medical  + + 
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Table 2. Laboratory and clinical data of suspected HIT patients with negative Annexin V-binding assay result 
 Patient  Laboratory results     Clinical data      Follow up   
 Male (M)/ EIA Annexin V Platelet MP  4T score Thrombosis Surgical  or  Alternative Platelet count 
 Female (F) (OD) binding assay assay    medical patient  anticoagulant recovery 
1 F 2.968 - -  3 - medical  - + 
2 M 2.664 - -  3 - surgical  + - 
3 M 2.450 - -  5 - medical  - + 
4 M 2.350 - -  4 - surgical  - death 
5 F 2.218 - -  3 - medical  - death 
6 F 2.031 - -  5 - surgical  + + 
7 M 1.381 - -  4 - surgical  - + 
8 F 1.316 - -  4 - medical  - -  
9 F 1.292 - -  5 - surgical  - - 
10 F 1.238 - -  5 - surgical  + - 
11 F 1.200 - -  4 - surgical  - death 
12 F 0.988 - -  5 - medical  + + 
13 M 0.939 - -  3 - surgical  - - 
14 F 0.903 - -  5 - medical  - + 
15 M 0.897 - -  4 - medical  - death 
16 F 0.865 - -  5 - surgical  + + 
17 M 0.809 - -  4 - surgical  - - 
18 M 0.775 - -  6 - surgical  - death 
19 F 0.697 - -  3 - surgical  - death  
20 F 0.694 - -  4 - medical  - + 
21 F 0.666 - -  4 - medical  - + 
22 M 0.636 - -  4 - medical  - death 
23 M 0.615 - -  5 - surgical  - + 
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